Cargando…

Levodopa Prescription Patterns in Patients with Advanced Parkinson's Disease: A Japanese Database Analysis

Prescription doses of levodopa in patients with advanced Parkinson's disease (PD) are generally lower in Japan than in the United States or Europe, although Japanese guidelines for the management of PD recommend increasing the dosage as the disease progresses. However, data regarding levodopa p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeda, Atsushi, Baba, Toru, Watanabe, Jun, Nakayama, Masahiko, Hozawa, Hiroyuki, Ishido, Miwako
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550461/ https://www.ncbi.nlm.nih.gov/pubmed/37799489 http://dx.doi.org/10.1155/2023/9404207

Ejemplares similares

Levodopa-carbidopa intestinal gel therapy may cause “Supra-ON freezing of gate” in patients with Parkinson's disease with diphasic dyskinesia
por: Oshiro, Saki, et al.
Publicado: (2021)

Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Continuous levodopa for advanced Parkinson’s disease
por: Lundqvist, Christofer
Publicado: (2007)

Levodopa-Induced Changes in Electromyographic Patterns in Patients with Advanced Parkinson’s Disease
por: Ruonala, Verneri, et al.
Publicado: (2018)

Off Time Independently Affects Quality of Life in Advanced Parkinson's Disease (APD) Patients but Not in Non-APD Patients: Results from the Self-Reported Japanese Quality-of-Life Survey of Parkinson's Disease (JAQPAD) Study
por: Hayashi, Yuka, et al.
Publicado: (2021)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
por: Antonini, Angelo
Publicado: (2009)

Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database
por: Suzuki, Masahiko, et al.
Publicado: (2020)

Prescription Pattern of Monoamine Oxidase B Inhibitors Combined with Levodopa: A Retrospective Observational Analysis of Italian Healthcare Administrative Databases
por: Ronconi, Giulia, et al.
Publicado: (2022)

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
por: Othman, Ahmed A., et al.
Publicado: (2015)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022)

Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease
por: Nomoto, Masahiro, et al.
Publicado: (2018)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

Levodopa treatment patterns in Parkinson’s disease: A retrospective chart review
por: Navaratnam, Prakash, et al.
Publicado: (2022)

Effect of Opicapone Tablets on Levodopa and 3‐O‐Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study
por: Nomoto, Masahiro, et al.
Publicado: (2020)

Efficacy and safety of levodopa–carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson’s disease patients
por: Murata, Miho, et al.
Publicado: (2016)

Levodopa-Responsive Benign Tremulous Parkinsonism
por: Kano, Osamu, et al.
Publicado: (2013)

Mortality in Levodopa-Treated Parkinson's Disease
por: Morgan, John C., et al.
Publicado: (2014)

Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa
por: Zadikoff, Cindy, et al.
Publicado: (2020)

Correlation between Serum Zinc Levels and Levodopa in Parkinson’s Disease
por: Matsuyama, Hirofumi, et al.
Publicado: (2021)

Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin
por: Nakayama, Masahiko, et al.
Publicado: (2015)

Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
por: Antonini, Angelo, et al.
Publicado: (2016)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2018)

Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease
por: Udd, Marianne, et al.
Publicado: (2017)

Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
por: Valldeoriola, Francesc, et al.
Publicado: (2021)

Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review
por: Tsunemi, Taiji, et al.
Publicado: (2021)

Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson's Disease
por: Nishijima, Haruo, et al.
Publicado: (2018)

Modulation of Habit Formation by Levodopa in Parkinson's Disease
por: Marzinzik, Frank, et al.
Publicado: (2011)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Schaeffer, Eva, et al.
Publicado: (2016)

Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease
por: Haddad, Fatma, et al.
Publicado: (2017)

Successful Utilization of Levodopa in HIV-Induced Parkinsonism
por: Almajali, Mohammad, et al.
Publicado: (2020)

Mechanisms of peripheral levodopa resistance in Parkinson’s disease
por: Beckers, Milan, et al.
Publicado: (2022)

Determinants of Levodopa Responsiveness in Patients with Vascular Parkinsonism
por: Goyal, Sheetal, et al.
Publicado: (2022)

Comparison of Endothelial Progenitor Cells in Parkinson's Disease Patients Treated with Levodopa and Levodopa/COMT Inhibitor
por: Lee, Phil Hyu, et al.
Publicado: (2011)

Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson’s disease
por: Fernandez, Hubert H, et al.
Publicado: (2016)

Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients
por: SÜCÜLLÜ KARADAĞ, Yeşim, et al.
Publicado: (2021)

The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England
por: Chaudhuri, K. Ray, et al.
Publicado: (2022)

Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson's disease
por: Diaconu, Ştefania, et al.
Publicado: (2023)

Hypnotic prescription trends and patterns for the treatment of insomnia in Japan: analysis of a nationwide Japanese claims database
por: Okuda, Shoki, et al.
Publicado: (2023)

Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
por: Mao, Zhongping, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qsb00dgp1858ar09tikd6che26